CC-671
Axon 3934
CAS:
1618658-88-0
Purity:
99%
- Soluble in DMSO
- MF: C28H28N6O4
- MW: 512.56
Description
CC-671 is a potent and selective dual inhibitor of TTK (Human Protein Kinase Monopolar Spindle 1 (hMps1)) / CLK2 (CDC2-like Kinase), with IC50 values of 5 nM and 3 nM, respectively, a unique feature targeting both TTK (mitotic exit) and CLK2 (mRNA splicing). It displays a strong single agent in vivo antitumor efficacy in multiple TNBC (Triple negative breast cancer) xenograft models.
More Information
| Parent CAS No. | 1618658-88-0 |
|---|---|
| Chemical Name | 4-(4-(Cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide |
| extra_info | Sold in collaboration with Chemietek |
| SMILES | C1(C(=O)NC)C=CC(NC2N=C(OC3CCCC3)C3C(C4C=CC5N=C(C)OC=5C=4)=CNC=3N=2)=C(OC)C=1 |
| MFCD | N.A. |
| InChi | InChI=1S/C28H28N6O4/c1-15-31-21-10-8-16(12-23(21)37-15)19-14-30-25-24(19)27(38-18-6-4-5-7-18)34-28(33-25)32-20-11-9-17(26(35)29-2)13-22(20)36-3/h8-14,18H,4-7H2,1-3H3,(H,29,35)(H2,30,32,33,34) |
| InChiKey | CWJLAVRXVFHDSJ-UHFFFAOYSA-N |
| CID | 117881270 |
| Short Description | TTK inhibitor |
References
- JR Riggs et al. The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen. J Med Chem. 2017 Nov 9;60(21):8989-9002.
- D Zhu et al. Synthetic lethal approach identifies potent and selective TTK and CLK inhibitor with preclinical anticancer activity in triple-negative breast cancer model Mol Cancer Ther (2018) 17 (1_Supplement): B177.
Other Categories
Get a Quote for
Loading...